Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone

Phase 4 Completed 201 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate medication satisfaction after at least 4 weeks of paliperidone ER (extended-release), an antipsychotic, treatment in patients with schizophrenia who were previously taking either 4 or 6 mg of risperidone daily by mouth, but who are not satisfied with their treatment.

Timeline

Start: 2007-10
Primary completion: 2008-07
Completion: 2008-07

Outcome

Met primary endpoint

paper MSQ score improved from 2.7 + or - 0.8 (very to somewhat dissatisfied) at baseline to 5.1 + or - 1.2 (somewhat satisfied) at endpoint (P<0.001). PMID 20216424 ↗

Publications

Canuso CM, Grinspan A, Kalali A, Damaraju CV, Merriman U, Alphs L, Awad AG. Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone. Int Clin Psychopharmacol. 2010 May;25(3):155-64. doi: 10.1097/YIC.0b013e3283372977.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Paliperidone	Unknown	6 mg	—
Subject	Paliperidone	Unknown	9 mg	—
Subject	Paliperidone	Unknown	12 mg	—
Subject	Risperidone	Other / unclassified	4 mg	Oral
Subject	Risperidone	Other / unclassified	6 mg	Oral